News - ramucirumab


Current filters:


Popular Filters

Lilly’s ramucirumab significantly improves overall survival in advanced gastric cancer patients


US pharma major Eli Lilly (NYSE: LLY) has announced positive results from the Phase III REGARD trial…

Eli LillyOncologyPharmaceuticalramucirumabResearch

Mixed Phase III results with Lilly’s ramucirumab

Mixed Phase III results with Lilly’s ramucirumab


US drug major Eli Lilly has announced top-line results from a global Phase III study of ramucirumab in…

Eli LillyNorth AmericaOncologyPharmaceuticalramucirumabResearch

US and European Rxing decisions on metastatic colorectal cancer


The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Eli Lilly's ramucirumab succeeds in Ph III gastric cancer study


US pharma major Eli Lilly (NYSE: LLY) revealed yesterday that the REGARD trial, a Phase III study of…

Eli LillyOncologyPharmaceuticalramucirumabResearch

Back to top